Risks of Kangfuxiaoyan suppository due to routes of administration

doi:10.19803/j.1672-8629.20220443

Abstract

Abstract: Objective To analyze the risk of Kangfuxiaoyan suppository related to routes of administration in order to provide reference for clinical rational drug use. Methods The cases of adverse drug reactions (ADR) reported in the national ADR monitoring system , related domestic literature, and precautions taken in China were summarized. The risks of Kangfuxiaoyan suppository due to vaginal administration were analyzed. Results A total of 1 916 cases of ADR related to Kangfuxiaoyan suppository were collected from the national adverse drug reaction monitoring system between 2004 and 2022. Kangfuxiaoyan suppository should have been administered rectally, but there were 215 cases of ADR caused by vaginal administration. The incidence of pain at the site of application, vulvovaginal pruritus, vulvovaginal discomfort, vulvovaginal burning sensation and allergic reactions was higher in these cases of ADR. Vaginal administration could affect the efficacy and cause such adverse reactions as vaginal irritation. Conclusion The drug label of Kangfuxiaoyan suppository has been upgraded under the requirement of National Medical Products Administration(NMPA). Drug marketing authorization holders should communicate more with health care providers and patients to control the safety risks related to vaginal administration of Kangfuxiaoyan suppository.

Key words: Kangfuxiaoyan suppository, rectal suppository, vaginal administration, adverse drug reaction, regulatory measures

CLC Number:

R994.11

ZHU Lan, JIN Zhe, LIU Lihong, ZHONG Lumiao, LIUXiaojun. Risks of Kangfuxiaoyan suppository due to routes of administration[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 306-310.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20220443

https://zgywjj.magtechjournal.com/EN/Y2023/V20/I3/306

References

[1] China Pharmaceutical Association Hospital Pharmacy Committee. Medication Errors (用药错误) [M]. Beijing: People’s Health Publishing House, 2017:3-5.
[2] National center for adverse drug reaction monitoring.Notice on Issuing the Adverse Drug Reaction Report Form for Marketing Authorization Holders and Instructions for Filling in the Form(Interim) [EB/OL]. (2022-01-08)[2022-06-21].https://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/202001/t20200108_47026.html.
[3] HUANG L.Efficacy of sequential therapy of cefoxitin sodium and levofloxacin combined with Kangfuxiaoyan Suppository in patients with chronic pelvic inflammatory disease and effect on inflammatory factors and recurrence rate[J].Anti-infection Pharmacy(抗感染药学), 2020, 90(1): 137-139.
[4] LUO M, WEI SB, HUANG L, et al.Efficacy and safety of Kangfuxiaoyan suppository combined with antibiotics for pelvic inflammatory disease:A systematic review and Meta analysis[J]. Chinese Journal of Antibiotics(中国抗生素杂志), 2019, 44(4): 519-526.
[5] LI P, XIE YM, SHI W, et al.Systemic evaluation and Meta-analysis of efficacy and safety of Kangfu Xiaoyan Suppository in treatment of pelvicinflammatory disease[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2019, 44(22): 4962-4974.
[6] CHEN SL.One case of allergic measles caused by Kangfuxiaoyan suppository[J]. Hebei Medicine(河北医学) , 1997, 3(6): 108.
[7] ZHU M,ZANG Q.One case of allergic reaction caused by Kangfuxiaoyan suppository[J]. Medical Herald(医药导报), 2002, 21(5): 146.
[8] XU XD.One case of allergic reaction caused by Kangfuxiaoyan suppository[J]. China Journal of Chinese Materia Medica(中国中药杂志), 1990, 15(4): 52.
[9] WANG LX, HOU LH, XIE YM, et al.Expert consensus statement on Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory in clinical practice[J]. China Journal of Chinese Materia Medica(中国中药杂志),2019, 44(20): 4350-4353.
[10] ZHU JF,CHEN JR.Research progress of rectal administration of traditional Chinese medicine[J].National Medical Journal of China(中华中医药杂志), 2013, 28(3): 768-771.
[11] PING QN, TU XD, ZHANG JS, et al.Pharmaceutics Edition 4(药剂学) [M].Beijing: People’s Health Publishing House, 2019.
[12] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China,Volume IV(中华人民共和国药典四部)[M]. Beijing: China Medical Science Press, 2020: 9-10.
[13] NMPA. NMPA Announcement on the Revision of the Package Insert of Kangfuxiaoyan suppository and Shedanchuanbei Preparations(No.42of2022)[EB/OL]. (2022-05-31) [2022-06-21]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20220531143951162.html.
[14] NMPA.NMPA Announcement on the Technical Guideline for t collecting and reporting individual cases of adverse drug reactions(No.131of2018) [EB/OL]. (2018-12-21) [2022-06-21]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20181221172901438.html.
[15] NMPA. Annual Report for National ADR Monitoring(2021) [EB/OL].(2022-03-30) [2022-06-21]. https://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20220329161925106.html.
[16] ZHANG XM, LIN ZJ, ZHANG B, et al.Interpretation of technical specifications for revision of safety information in marketed Chinese patent medicine instructions[J]. China Journal of Chinese Materia Medica(中国中药杂志) , 2022, 47(2): 295-300.
[17] NMPA. NMPA Announcement on the Technical Guideline for the Revision of Safety Information Items in Package Inserts of Marketed Traditional Chinese Medicines (Interim) (No.1of2022) [EB/OL].(2022-01-07) [2022-06-21] .https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20220107145808154.html.